Get the Stockscreener App
141.39
1.38%
1.8482
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Merck Co Inc stock is traded at $141.39, with a volume of 5.22M.
It is up +1.38% in the last 24 hours and down -5.90% over the past month.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
See More
Previous Close:
$139.54
Open:
$140.13
24h Volume:
5.22M
Relative Volume:
0.55
Market Cap:
$348.40B
Revenue:
$65.51B
Net Income/Loss:
$8.93B
P/E Ratio:
39.79
EPS:
3.5532
Net Cash Flow:
$14.12B
1W Performance:
-5.24%
1M Performance:
-5.90%
6M Performance:
+17.06%
1Y Performance:
+59.30%
1-Day Range:
$139.74
$142.16
1-Week Range:
$138.80
$149.27
52-Week Range:
$82.01
$156.92
Merck Co Inc Stock (MRK) Company Profile
Name
Merck Co Inc
Sector
Industry
Phone
908-740-4000
Address
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK vs LLY, JNJ, ABBV, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
141.22 | 354.80B | 65.51B | 8.93B | 14.12B | 3.5532 |
LLY
Lilly Eli Co
|
1,156.91 | 1.02T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
254.96 | 623.34B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
266.63 | 459.33B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
140.75 | 268.10B | 54.66B | 13.58B | 16.05B | 7.0171 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Feb-13-26 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-08-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-18-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-24-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Oct-13-25 | Resumed | Citigroup | Neutral |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-18-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-10-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-08-25 | Downgrade | Truist | Buy → Hold |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Dec-04-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-11-24 | Downgrade | Daiwa Securities | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Mar-11-24 | Downgrade | Societe Generale | Hold → Sell |
| Jan-04-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-27-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Oct-20-23 | Upgrade | UBS | Neutral → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Hold |
| Apr-13-23 | Upgrade | Citigroup | Neutral → Buy |
| Mar-28-23 | Downgrade | Societe Generale | Buy → Hold |
| Mar-13-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-06-23 | Initiated | Jefferies | Buy |
| Feb-22-23 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-04-23 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Oct-10-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-14-22 | Upgrade | Berenberg | Hold → Buy |
| Jul-06-22 | Upgrade | Daiwa Securities | Neutral → Buy |
| Jun-06-22 | Resumed | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-16-21 | Initiated | Daiwa Securities | Neutral |
| Dec-13-21 | Downgrade | UBS | Buy → Neutral |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Dec-07-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-29-21 | Downgrade | Citigroup | Buy → Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-01-21 | Upgrade | Argus | Hold → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-27-21 | Resumed | Truist | Buy |
| May-20-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Aug-03-20 | Upgrade | Goldman | Neutral → Buy |
| Jun-12-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-16-19 | Initiated | SVB Leerink | Outperform |
| Jul-03-19 | Initiated | Mizuho | Buy |
| May-28-19 | Initiated | Goldman | Neutral |
| May-13-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-16-18 | Reiterated | Citigroup | Buy |
| Oct-09-18 | Resumed | Guggenheim | Buy |
| Apr-23-18 | Upgrade | Goldman | Neutral → Buy |
| Apr-17-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-05-18 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-12-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Feb-14-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-07-18 | Reiterated | Morgan Stanley | Equal-Weight |
| Jan-16-18 | Upgrade | SunTrust | Hold → Buy |
View All
Merck Co Inc Stock (MRK) Latest News
Merck (MRK) director receives 55.9149 stock-linked units, payable entirely in cash - Stock Titan
Merck (MRK) director receives 111.8299 stock-linked units, payable 100% in cash after service ends. - Stock Titan
Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study - Zacks Investment Research
Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29 - Business Wire
Merck reports tulisokibart results for Merck & Co. stock - AD HOC NEWS
Merck Says Investigational Skin Therapy Shows Potential - Benzinga
Merck nabs mid-stage trial win for skin disease drug (MRK:NYSE) - Seeking Alpha
Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - GlobeNewswire Inc.
Head and Neck Squamous Cell Carcinoma (HNSCC)Market Insights, Epidemiology, and Market Forecast - GlobeNewswire Inc.
A Look at Merck & Co Inc (MRK) After 0.4% Gain -- GF Value $120. - GuruFocus
Merck & Co., Inc. (NYSE:MRK) Stock Price Target Raised at Scotiabank - MarketBeat
Merck Inks $2.1B Deal With Chinese Biotech to Expand Oncology Pipeline - TradingView
Merck & Co (MRK) Has Billions in Revenue to Defend. Can its Pipeline Do the Job? - Yahoo Finance
What Is Driving the Latest Milestones at Merck (NYSE:MRK)? - kalkinemedia.com
Merck, Daiichi Sankyo Pull FDA Application for Lung Cancer DrugMerck & Co (NYSE:MRK) - Benzinga
Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion - reuters.com
Daiichi, Merck withdraw BLA for B7-H3 ADC in small-cell lung cancer - BioWorld News
FDA Expands Merck's Welireg Label for a New Kidney Cancer Indication - TradingView
Merck closes SciBrunch KRAS licence worth up to US$2.13B - Mugglehead Investment Magazine
Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor - Business Wire
Merck & Co. stock trades at USD 148.74 after pipeline updates - AD HOC NEWS
B7-H3 ADC Field Opens As Merck & Co. Pulls US Filing - insights.citeline.com
Merck (NYSE:MRK) In Focus As Oncology Advances And Pipeline Readouts Lift Its Shares Toward Rare Heights - kalkinemedia.com
Merck, Daiichi pull US application for second partnered cancer therapy - reuters.com
Here’s How Much You Would Have Made Owning Merck & Co Stock In The Last 5 Years - Benzinga
Merck, Daiichi withdraw ifinatamab FDA application - Mugglehead Investment Magazine
Merck & Co. stock is last at USD 147.97, down 0.01 percent in New York trading - AD HOC NEWS
Merck stock climbs 2.0 percent ahead of the open - AD HOC NEWS
Moderna Stock Trends After HoursModerna (NASDAQ:MRNA), Merck & Co (NYSE:MRK) - Benzinga
Alpha Buying: Follow the Money From NVIDIA and Merck - Benzinga
Merck Says Investigational Diabetes-Related Blindness Drug at Par With Roche’s Medicine - Benzinga
What Is Driving the Latest Milestones at Merck & Co. (NYSE:MRK)? - Kalkine Media
Merck's drug for diabetes-related eye disease meets trial goal - reuters.com
Merck says remigromig met BRUNELLO vision endpoint, flags eye risks - Mugglehead Investment Magazine
Merck & Co. stock falls 1.86 percent as Q2 sales rise - AD HOC NEWS
Merck's experimental eye drug met its vision goal, but eye bleeding rates were higher than with the other drug - Stock Titan
Envestnet Portfolio Solutions Inc. Has $13.56 Million Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Envestnet Asset Management Inc. Has $513.60 Million Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck and Co. stock falls 1.9 percent before the bell - AD HOC NEWS
QRG Capital Management Inc. Lowers Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck (MRK) Declines More Than Market: Some Information for Investors - Yahoo Finance
Merck stock falls 2.63 percent at the close - AD HOC NEWS
Merck pipeline seen driving potential re-rating as clinical catalysts approach - Proactive financial news
Merck & Co. stock gains as Japan clears Keytruda injection - AD HOC NEWS
Merck and Co. stock gains 0.94 percent ahead of the open - AD HOC NEWS
Merck stock gains 1.97 percent at the close - AD HOC NEWS
State Street Corp Has $15.57 Billion Position in Merck & Co., Inc. $MRK - MarketBeat
MRK|Merck & Co Inc|Price:150.910|Chg%:+1.410 - TradingKey
Merck & Co. stock falls 36.58 percent year to date - AD HOC NEWS
Merck & Co., Inc. $MRK Shares Bought by Andra AP fonden - MarketBeat
Merck: Time To Trim, Overvalued, And Overbought (Rating Downgrade) (NYSE:MRK) - Seeking Alpha
Merck Co Inc Stock (MRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.10%
1.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):